The nation of Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (£272m) over five years due to the United States' request for sensitive data.
This move became public following a government memo from December was leaked, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".
A government representative has since clarified that the United States was demanding access to biological samples for scientific study and commercial purposes while refused to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further negotiations to reach a deal suitable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a court suspended a related health funding agreement after legal challenges were filed about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral deals to enhance openness and accountability.
According to statements, Sixteen African countries have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data for a long time, without any corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the end products would be accessible to our citizens if a new pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems previously set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This system is designed to guarantee that when a country contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future collaboration could be arranged in a manner that respects the sovereignty and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but urged that talks should continue since much of the nation's HIV programmes were funded by foreign aid.
"If technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group said.
This impasse emphasises the complex debate between accepting crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.